Search Clinical Trials in the European Union

1-2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
481-500 of 653 trials

Melanoma with Brain Metastases: Immunotherapy Study

We are studying the effects of immunotherapy in melanoma patients with brain metastases who are also receiving steroid treatment. Our goal is to see if this combination improves outcomes compared to standard care.

Malignant Melanoma of Skin1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesNeurologyOncology

Chronic Kidney Disease: Optimizing Tacrolimus Dosage with Genetic Testing

We are studying whether a genetic testing strategy can help tailor tacrolimus dosing for patients with chronic kidney disease before kidney transplantation. This may improve treatment outcomes and reduce side effects.

Kidney Transplant1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesInternal MedicineNephrology

Diabetic Cardiovascular Autonomic Neuropathy: The FibroCAN Study

We are investigating whether finerenone can help improve heart function and reduce nerve damage in people with type 2 diabetes and early-stage cardiovascular autonomic neuropathy. This study compares the treatment to a placebo to assess its effects.

Diabetic Cardiovascular Autonomic Neuropathy1-2 yearsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementCardiologyEndocrinologyNeurology

Activated T-Cells for Graft vs Host Disease After Stem Cell Transplant

We are testing a new treatment using activated regulatory T-cells in patients shortly after stem cell transplantation. The aim is to see if it can safely reduce the risk and severity of acute graft vs host disease.

LeukaemiaAcute graft versus host disease1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Crizotinib for Children with Severe Type 2 Neurofibromatosis

We are studying whether crizotinib can help reduce tumor size in children with severe type 2 neurofibromatosis who are not eligible for surgery or radiotherapy. We will also evaluate the safety of this treatment.

Neurofibromatosis Type 21-2 yearsEfficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesNeurologyOncology

Kidney Transplant in Children: Prolonged-Release Tacrolimus Study

We are studying a new form of tacrolimus for children who have undergone kidney transplantation. The goal is to see if it works as well and is as safe as the current version used.

Caucasian Pediatric Kidney Transplant Recipients1-2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesNephrologyPediatrics

Acromegaly: Debio 4126 Treatment Study

We are testing a new formulation of Debio 4126 in patients with acromegaly who have been treated with other medications. The study aims to see if it helps maintain normal hormone levels and evaluates its safety compared to a placebo.

Acromegaly1-2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementEndocrinology

Pain Medication Tapering for Persistent Spinal Pain

We are studying how different methods of reducing pain medication affect disability in patients with Persistent Spinal Pain Syndrome Type II after spinal cord stimulation. This research may help improve pain management strategies.

Persistent Spinal Pain Syndrome Type II1-2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteInternal MedicineNeurologyOrthopedics and Traumatology

Multiple Sclerosis: Masitinib Treatment Study

We are investigating whether the oral medication masitinib is effective and safe for people with primary or secondary progressive multiple sclerosis without relapses. This study compares masitinib to a placebo to evaluate its impact on various symptoms and overall health.

Multiple Sclerosis1-2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesPartially RemoteNeurology

Granulomatosis with Polyangiitis: New Salvage Therapies

We are testing different treatment combinations for patients who haven't responded to standard care for granulomatosis with polyangiitis. The goal is to find the most effective way to help induce remission and improve overall health.

Granulomatosis with Polyangiitis (GPA)1-2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesInternal MedicineRheumatology

Eosinophilic Esophagitis: EP 104GI Treatment Study

We are testing a new treatment called EP 104GI for adults with eosinophilic esophagitis. The study aims to evaluate its safety and effectiveness in reducing symptoms and improving esophageal health.

Eosinophilic Esophagitis1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesAllergologyGastroenterology

MMRd Uterine Cancer: Pembrolizumab Treatment Study

We are investigating whether pembrolizumab can effectively treat MMRd uterine cancer before surgery. The study will assess how well it works and its safety for patients.

Endometrial Cancer1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementGynecology and ObstetricsOncology

Cutaneous Lupus Erythematosus: IMVT-1402 Study

We are evaluating a new treatment for people with active cutaneous lupus erythematosus to see if it improves skin symptoms compared to a placebo. This study aims to assess its safety and effectiveness.

Skin Lupus1-2 yearsEfficacy phase (II)Investigational MedicinesCost ReimbursementDermatologyRheumatology

Multiple Myeloma: [68Ga]Ga-PentixaFor Imaging Study

We are exploring a new imaging method to see how well it detects multiple myeloma lesions in patients at diagnosis or relapse. This study may help improve the way we monitor and treat this condition.

Multiple Myeloma1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Setmelanotide for ROHHAD Syndrome

We are studying the effects of setmelanotide on hypothalamic function and related symptoms in patients with ROHHAD syndrome. This trial aims to understand how the treatment may improve various health aspects over time.

ROHHAD Syndrome1-2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteEndocrinologyInternal Medicine

COVID-19 Booster: CD40.Pan.CoV Vaccine

We are testing a new vaccine to see if it safely boosts immunity in adults. This study will help us understand its effectiveness as a booster shot.

Healthy Participants1-2 yearsSafety phase (I)Infectious Diseases

Nivolumab for ALK+ Anaplastic Large Cell Lymphoma

We are studying the effects of nivolumab in patients with relapsed or refractory ALK+ anaplastic large cell lymphoma. This trial looks at its effectiveness for those with progressive disease and as a follow-up treatment for those in remission.

Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncologyPediatrics

Advanced Solid Tumors: MK-8294 Treatment

We are evaluating a new treatment called MK-8294 for people with advanced solid tumors. The study aims to understand its safety and how well it works.

Breast CancerCervical Squamous Cell CarcinomaEndometrial Carcinoma1-2 yearsSafety phase (I)Oncology

Parkinson's Disease: Investigational Drug ARV-102

We are studying the safety and effects of ARV-102 in patients with Parkinson's disease. This research aims to understand how well the drug is absorbed and its potential benefits.

Parkinson's Disease1-2 yearsSafety phase (I)Neurology

ADCE-D01 for Metastatic Soft Tissue Sarcoma

We are testing a new treatment called ADCE-D01 in patients with metastatic or unresectable soft tissue sarcoma. The study aims to evaluate its safety and how well it may help fight the cancer.

Soft Tissue Sarcoma1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology